Asparaginase and steroids are significant risk factors for venous thromboembolism (VTE), as they interfere with levels of natural anticoagulants leading to suboptimal treatment responses in ALL patients, and there are currently no proven preventive strategies for VTE during ALL treatment [69,70,71]. The gene discussed is ASPG; the disease is acute lymphoblastic leukemia.